Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Single Arm Extension Study to Further Evaluate the Safety, Tolerability and Treatment Response of GBT440 in Patients With Sickle Cell Disease Who Participated in the Phase 1 Study GBT440-001

Trial Profile

An Open Label Single Arm Extension Study to Further Evaluate the Safety, Tolerability and Treatment Response of GBT440 in Patients With Sickle Cell Disease Who Participated in the Phase 1 Study GBT440-001

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Voxelotor (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Sponsors Global Blood Therapeutics
  • Most Recent Events

    • 29 Jan 2019 According to a Global Blood Therapeutics media release, data from the phase 1/2 study (NCT02285088) and the open-label extension (NCT03041909) were published in the online Journal Blood, a peer-reviewed publication of the American Society of Hematology.
    • 17 Jan 2019 Results of multiple doses of voxelotor in patients published in the Blood.
    • 13 Feb 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top